Compare AbbVie Inc (ABBV) vs Vanguard Total International Bond Index Fund ETF (BNDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Vanguard Total International Bond Index Fund ETF — how do they compare? AbbVie Inc trades at $249.8 (market cap $441.94B), while Vanguard Total International Bond Index Fund ETF trades at $47.83. The key difference: AbbVie Inc pays a 2.77% dividend while Vanguard Total International Bond Index Fund ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | BNDX | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | — |
52-Week High | $263.58 | $49.91 |
52-Week Low | $197.38 | $47.57 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
BNDX trades at $47.91, up 0.25% with neutral technical signals. The ETF shows mixed institutional activity with Apella Capital reducing holdings by 3.0% while Archer Investment increased by 48.2% in Q2 2026. Recent dividend payments of $0.11-$0.12 provide income appeal, though key valuation ratios remain unavailable for analysis.
Outlook remains balanced amid bond market volatility. Rising Treasury yields and inflation concerns create headwinds, while institutional interest and steady dividends offer support. The ETF's international bond exposure provides diversification benefits but remains sensitive to global interest rate movements and geopolitical tensions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →
